Inventiva completes last patient visit in NATiV3 Phase III trial for MASH

Inventiva S.A. announced on September 2, 2026 that the last patient had completed the final 72-week visit in the NATiV3 clinical trial evaluating lanifibranor in patients with MASH.¹ Following completion of the treatment period, the company expects to report topline results in the fourth quarter of 2026.¹ This follows an earlier milestone in April 2025, when Inventiva announced the completion of patient enrollment in NATiV3 with the randomization of the last patient in the main cohort.¹

If the Phase III results are positive, the company targets a potential new drug application submission for lanifibranor in the first half of 2027, with a view to potential commercialization in 2028.¹

On the corporate side, Inventiva said on August 31, 2026, it appointed Chris Benecchi as Chief Operating Officer, who will lead operational readiness as the company approaches the expected topline results from NATiV3 in the fourth quarter of 2026 and prepares for potential commercialization, subject to regulatory approvals.¹

In June 2026, Inventiva executed a comprehensive refinancing described as an equity offering, transactions with the European Investment Bank, and a debt financing arrangement. The equity offering generated gross proceeds of $120.0 million, with net proceeds of $110.9 million after fees.¹ Separately, the company entered a subscription agreement with funds managed by BlackRock and Claret Capital Partners for senior secured debt of up to €130.0 million, plus an optional €20.0 million tranche contingent on FDA approval of the lanifibranor NDA.¹

On liquidity, the company said as of June 30, 2026, cash and cash equivalents totaled €166.1 million, with short-term deposits of €67.8 million,¹ and it expects, accounting for the June financing, to fund operations through the end of the second quarter of 2027.¹ The company said its current cash position remains insufficient to cover all projected operating needs over the next 12 months.¹